• Users Online: 179
  • Print this page
  • Email this page
Year : 2022  |  Volume : 26  |  Issue : 3  |  Page : 48-50

Peripheral neuropathy associated with tofacitinib use in alopecia universalis

1 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2 Department of Dermatology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Correspondence Address:
Dr. Fatimah Alowirdi
Department of Dermatology, King Abdulaziz Medical City, Riyadh
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jdds.jdds_69_19

Rights and Permissions

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss. Traditional medical therapies for AA include topical and intralesional corticosteroids, topical anthralin immunotherapy, and light therapy. Tofacitinib is a Janus kinase-1 and 3 inhibitor used in the treatment of AA. In this report, we describe a 20-year-old female with AU refractory to topical therapies; thus, she was started on tofacitinib. Mild peripheral neuropathy was an unanticipated side effect that could be kept into consideration.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded64    
    Comments [Add]    

Recommend this journal